- ticket title
- Changing habits: China’s pig farms clean up to beat swine fever
- Biden cancer group shuts down operations
- Britain tells Canada and France to pull their weight on Ebola
- Opioid ‘kingpin’ J&J fueled epidemic, Oklahoma argues at trial’s end
- High blood pressure, high cholesterol early in life tied to heart problems later
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo
ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients.
Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumors, across 10 different tumor types, including those with central nervous system metastases.
Reporting by John Miller; Editing by Michelle Martin